| S9414 |
Cyasterone |
Cyasterone is the main phytoecdysteroid component found in Cyathula capitata. It is a natural EGFR inhibitor and maybe a promising anti-cancer agent. |
Selective |
|
| S1054 |
AG99 |
AG99 (Tyrphostin 46,Tyrphostin A46,Tyrphostin B40) is a potent and selective inhibitor of EGFR. |
Selective |
|
| S5078 |
Osimertinib mesylate |
Osimertinib mesylate (AZD9291) is the mesylate form of osimertinib, which is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug. |
Selective |
|
| S8312 |
NSC228155 |
NSC228155 is an activator of EGFR. It binds to the sEGFR dimerization domain II and modulates EGFR tyrosine phosphorylation. |
Selective |
|
| S0151 |
AG-1557 |
AG-1557 is a specific and ATP competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. |
Selective |
|
| S6523 |
RG14620 |
RG14620 (Tyrphostin RG14620), an EGFR inhibitor of the tyrphostin family, directly inhibits the transport function of ABCG2/BCRP. |
Selective |
|
| S0324 |
Tyrphostin AG30 (AG30) |
Tyrphostin AG30 (AG30), a potent and selective EGFR tyrosine kinase inhibitor, selectively inhibits self renewal induction by c-ErbB, and is able to inhibit activation of STAT5 by c-ErbB in primary erythroblasts. |
Selective |
|
| S9711 |
CH7233163 |
CH7233163 is a non-covalent ATP competitive inhibitor of EGFR-tyrosine kinase with antitumor activities against tumor with EGFR-Del19/T790M/C797S. |
Selective |
|
| S4667 |
Lidocaine hydrochloride |
Lidocaine hydrochloride (Lidothesin, Lignocaine, Xyloneural) is an inhibitor of epidermal growth factor receptor (EGFR) and has antiproliferative effect on human tongue cancer cells. Lidocaine hydrochloride is a local anesthetic and cardiac depressant used as an antiarrhythmia agent. |
Selective |
|
| S8920 |
(Rac)-JBJ-04-125-02 |
(Rac)-JBJ-04-125-02 (JBJ-04-125-02 racemate) is a mutant-selective allosteric inhibitor of Epidermal growth factor receptor (EGFR) with potential anticancer activity. |
Selective |
|
| S1079 |
PD153035 HCl |
PD153035 HCl (SU-5271 HCl, AG1517 HCl, ZM 252868 HCl) is a potent and specific inhibitor of EGFR with Ki and IC50 of 5.2 pM and 29 pM in cell-free assays; little effect noted against PGDFR, FGFR, CSF-1, InsR and Src. |
Selective |
EGFR, Ki: 5.2 pM |
| S6546 |
PD153035 |
PD153035 is a specific and potent inhibitor of the epidermal growth factor (EGF) receptor tyrosine kinase (Ki = 5.2 pM). |
Selective |
EGFR, Ki: 5.2 pM |
| S7971 |
Zorifertinib (AZD3759) |
Zorifertinib (AZD3759) is a potent, oral active, CNS-penetrant EGFR inhibitor with IC50 of 0.3 nM, 0.2 nM, and 0.2 nM for EGFR (WT), EGFR (L858R), and EGFR (exon 19Del), respectively. Phase 1.
|
Selective |
EGFR (WT), IC50: 0.3 nM; EGFR (L858R), IC50: 0.2 nM; EGFR (exon 19Del), IC50: 0.2 nM |
| S7557 |
CL-387785 (EKI-785) |
CL-387785 (EKI-785, WAY-EKI 785) is an irreversible, and selective EGFR inhibitor with IC50 of 370 pM.
|
Selective |
EGFR, IC50: 370 pM |
| S7039 |
PD168393 |
PD168393 is an irreversible EGFR inhibitor with IC50 of 0.70 nM, irreversibly alkylate Cys-773; inactive against insulin, PDGFR, FGFR and PKC. |
Selective |
EGFR, IC50: 0.70 nM |
| S1170 |
WZ3146 |
WZ3146 is a mutant-selective irreversible inhibitor of EGFR(L858R) and EGFR(E746_A750) with IC50 of 2 nM and 2 nM; does not inhibit ERBB2 phosphorylation (T798I). |
Selective |
EGFR (L858R), IC50: 2 nM; EGFR (E746_A750), IC50: 2 nM; EGFR (L858R/T790M), IC50: 5 nM; EGFR (E746_A750/T790M), IC50: 14 nM |
| S7786 |
Erlotinib |
Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy. |
Selective |
EGFR, IC50: 2 nM |
| S1023 |
Erlotinib HCl |
Erlotinib HCl is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. |
Selective |
HER1/EGFR, IC50: 2 nM |
| S2205 |
OSI-420 |
OSI-420 (DesMethyl Erlotinib, CP-473420) is the active metabolite of Erlotinib (EGFR inhibitor with IC50 of 2 nM). |
Selective |
EGFR, IC50: 2 nM |
| S1173 |
WZ4002 |
WZ4002 is a novel, mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM in BaF3 cell line; does not inhibit ERBB2 phosphorylation (T798I). |
Selective |
EGFR (L858R), IC50: 2 nM; EGFR (L858R/T790M), IC50: 8 nM |
| S2728 |
AG-1478 |
AG-1478 is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA). |
Selective |
EGFR, IC50: 3 nM |
| S2867 |
WHI-P154 |
WHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation. |
Selective |
EGFR, IC50: 4 nM |
| S1006 |
Saracatinib (AZD0530) |
Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Saracatinib induces autophagy. Phase 2/3. |
Selective |
EGFR (L861Q), IC50: 4 nM; EGFR (L858R), IC50: 5 nM; EGFR, IC50: 66 nM |
| S2922 |
Icotinib (BPI-2009H) |
Icotinib (BPI-2009H) is a potent and specific EGFR inhibitor with IC50 of 5 nM, including the EGFR, EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R). |
Selective |
EGFR, IC50: 5 nM |
| S7297 |
Osimertinib (AZD9291) |
Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3. |
Selective |
Exon 19 deletion EGFR, IC50: 12.92 nM; L858R/T790M EGFR, IC50: 11.44 nM; WT EGFR, IC50: 493.8 nM |
| S0070 |
Gefitinib-based PROTAC 3 |
Gefitinib-based PROTAC 3 which conjugates an EGFR binding element to a VHL ligand via a linker induces degradation of EGFR and mutants with DC50 of 11.7 nM and 22.3 nM in HCC827(Exon 19 del) and H3255 (L858R) cells, respectively. |
Selective |
EGFR, DC50: 11.7 nM; EGFR, DC50: 22.3 nM |
| S5098 |
Gefitinib hydrochloride |
Gefitinib (ZD1839) is an EGFR inhibitor with IC50s of 15.5 nM and 823.3 nM for WT EGFR and EGFR (858R/T790M), respectively. |
Selective |
EGFR, IC50: 15.5 nM |
| S0360 |
EGFR Inhibitor |
EGFR inhibitor, a cell permeable, 4,6-disubstituted pyrimidine compound, is a highly selevtive inhibitor of EGFR kinase with IC50 of 21 nM. EGFR inhibitor directly depolymerizes microtubules and is used as a chemical probe to investigate both the EGFR pathway and microtubule dynamics. |
Selective |
EGFR, IC50: 21 nM |
| S7284 |
Rociletinib (CO-1686) |
Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT in cell-free assays, respectively. Phase 2. |
Selective |
EGFR (L858R/T790M), Ki: 21.5 nM; EGFR (wt), Ki: 303.3 nM |
| S1025 |
Gefitinib |
Gefitinib is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway. |
Selective |
Tyr1173 (NR6wtEGFR cells), IC50: 37 nM; Tyr992 (NR6wtEGFR cells), IC50: 37 nM; Tyr1173 (NR6W cells), IC50: 26 nM; Tyr992 (NR6W cells), IC50: 57 nM |
| S7926 |
Lifirafenib (BGB-283) |
Lifirafenib (BGB-283, Beigene-283) potently inhibits RAF family kinases and EGFR activities in biochemical assays with IC50 values of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant.
|
Selective |
EGFR, IC50: 29 nM |
| S1392 |
Pelitinib (EKB-569) |
Pelitinib (EKB-569) is a potent irreversible EGFR inhibitor with IC50 of 38.5 nM. Pelitinib (EKB-569) also slightly inhibits Src, MEK/ERK and ErbB2 with IC50s of 282 nM, 800 nM and 1255 nM, respectively. Phase2. |
Selective |
EGFR, IC50: 38.5 nM |
| S1143 |
AG-490 (Tyrphostin B42) |
AG-490 (Tyrphostin B42, Zinc02557947) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src. |
Selective |
EGFR, IC50: 0.1 μM |
| S1046 |
Vandetanib |
Vandetanib is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay. It also inhibits VEGFR3 and EGFR with IC50 of 110 nM and 500 nM, respectively. Not sensitive to PDGFRβ, Flt1, Tie-2 and FGFR1 with IC50 of 1.1-3.6 μM. No activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R with IC50 above 10 μM. Vandetanib (ZD6474) increases apoptosis and induces autophagy by increasing the level of reactive oxygen species (ROS). |
Selective |
EGFR, IC50: 500 nM |
| S6525 |
AG 555 |
AG-555 (Tyrphostin B46) is an inhibitor of tyrosine kinase, interacts directly with topoisomerase I, thus preventing DNA relaxation. It inhibits EGFR with an IC50 of 0.7 μM. |
Selective |
EGFR, IC50: 0.7 μM |
| S6509 |
AG 494 |
AG-494, a member of the tyrphostin family of tyrosine kinase inhibitors, is a potent inhibitor of EGF receptor autophosphorylation (IC50=1.2 μM) and EGF-dependent cell growth (IC50=6 μM). |
Selective |
EGFR, IC50: 1.2 μM |
| S2115 |
RG 13022 |
RG 13022 (Tyrphostin RG13022) inhibits the autophosphorylation reaction of the EGF receptor in immunoprecipitates with IC50 of 4 µM. |
Selective |
EGFR, IC50: 4 μM |
| S0736 |
AG 556 |
AG-556 is a potent EGFR tyrphostin inhibitor with an IC50 of 5µM which suppresses the EGF-induced growth of HER14 cell. |
Selective |
EGFR, IC50: 5 μM |
| S2554 |
Daphnetin |
Daphnetin, a natural coumarin derivative, is a protein kinase inhibitor, inhibits EGFR, PKA and PKC with IC50 of 7.67 μM, 9.33 μM and 25.01 μM, respectively, also known to exhibit anti-inflammatory and anti-oxidant activities. |
Selective |
EGFR, IC50: 7.67 μM |
| S8009 |
AG-18 |
AG-18 (RG-50810, Tyrphostin A23, TX 825) inhibits EGFR with IC50 of 35 μM. |
Selective |
EGFR, IC50: 35 μM |
| S6809 |
SU5214 |
SU5214 is a inhibitor of VEGF receptor 2 (VEGFR2/FLK-1) with IC50 of 14.8 µM and EGFR with IC50 of 36.7 µm, respectively. |
Selective |
EGFR, IC50: 36.7 μM |
| S2895 |
Tyrphostin 9 |
Tyrphostin 9 (SF 6847, RG-50872) is firstly designed as an EGFR inhibitor with IC50 of 460 μM, but is also found to be more potent to PDGFR with IC50 of 0.5 μM. |
Selective |
EGFR, IC50: 460 μM |
| S3759 |
Norcantharidin |
Norcantharidin (Endothall anhydride) is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers. |
Selective |
|
| S6541 |
MTX-211 |
MTX-211 is a first-in-class dual inhibitor of PI3K and EGFR kinase. |
Selective |
|
| S6899 |
Licochalcone D |
Licochalcone D (Lico D, LCD, LD), a flavonoid isolated from a Chinese medicinal plant Glycyrrhiza inflata, has antioxidant, anti-inflammatory and anti-cancer properties. Licochalcone D inhibit phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone D inhibits JAK2, EGFR and Met (c-Met) activities and induces ROS-dependent apoptosis. Licochalcone D also induces caspases activation and poly (ADP-ribose) polymerase (PARP) cleavage. |
Selective |
|
| S2406 |
Chrysophanic Acid |
Chrysophanic Acid (Chrysophanol) a natural anthraquinone isolated from Dianella longifolia, is a EGFR/mTOR pathway inhibitor. |
Selective |
|
| S6868 |
Alflutinib (AST2818) mesylate |
Alflutinib (AST2818, Furmonertinib) mesylate is a third-generation epidermal growth factor receptor (EGFR) inhibitor that inhibits both EGFR-sensitive mutations and T790M mutations. Alflutinib (AST2818), primarily metabolized by CYP3A4, is also a potent CYP3A4 inducer with EC50 of 0.25 μM. |
Selective |
|
| S1179 |
WZ8040 |
WZ8040 is a novel mutant-selective irreversible EGFRT790M inhibitor, does not inhibit ERBB2 phosphorylation (T798I). |
Selective |
|
| S1342 |
Genistein (NPI 031L) |
Genistein (NPI 031L), a phytoestrogen found in soy products, is a highly specific inhibitor of protein tyrosine kinase (PTK) which blocks the mitogenic effect mediated by EGF on NIH-3T3 cells with IC50 of 12μM or by insulin with IC50 of 19 μM. |
Selective |
|
| S8036 |
Butein |
Butein, a plant polyphenol isolated from Rhus verniciflua, is able to inhibit the activation of protein tyrosine kinase, NF-κB and STAT3, also inhibits EGFR. |
Selective |
|
| S8412 |
Naquotinib(ASP8273) |
Naquotinib (ASP8273) is an orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. |
Pan |
|
| S9786 |
BDTX-189 |
BDTX-189 is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations with Kd of 0.2 nM, 0.76 nM, 13 nM and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. BDTX-189 exhibits anticancer activity. |
Pan |
EGFR, Kd: 0.2 nM |
| S7810 |
Afatinib Dimaleate |
Afatinib Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy. |
Pan |
EGFR (L858R), IC50: 0.4 nM; EGFR (wt), IC50: 0.5 nM; EGFR (L858R/T790M), IC50: 10 nM |
| S1011 |
Afatinib |
Afatinib inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFRwt, EGFR L858R , EGFR L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy. |
Pan |
EGFR (wt), IC50: 0.5 nM; EGFR (L858R), IC50: 0.4 nM; EGFR (L858R/T790M), IC50: 10 nM |
| S2185 |
Allitinib tosylate |
Allitinib tosylate (AST-1306 TsOH, AST-6) is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases. |
Pan |
EGFR, IC50: 0.5 nM; EGFR (T790M/L858R), IC50: 12 nM |
| S2733 |
AV-412 free base |
AV-412 free base (MP-412 free base) is an EGFR inhibitor with IC50s of 0.75, 0.51, 0.79, 2.30, 19 nM for EGFR, EGFRL858R, EGFRT790M, EGFRL858R/T790M and ErbB2, respectively. |
Pan |
EGFR, IC50: 0.75 nM |
| S7298 |
AZ5104 |
AZ5104, the demethylated metabolite of AZD-9291, is a potent EGFR inhibitor with IC50 of <1 nM, 6 nM, 1 nM, and 25 nM for EGFR (L858R/T790M), EGFR (L858R), EGFR (L861Q), and EGFR (wildtype), respectively. Phase 1. |
Pan |
EGFR (L858R/T790M), IC50: <1 nM; EGFR (L858R), IC50: 6 nM; EGFR (L861Q) , IC50: 1 nM; EGFR (wildtype), IC50: 25 nM |
| S6897 |
Epertinib hydrochloride |
Epertinib hydrochloride (S-222611 hydrochloride) is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER2 and HER4 with IC50 of 1.48 nM, 7.15 nM and 2.49 nM, respectively. Epertinib hydrochloride (S-222611 hydrochloride) exhibits antitumor activity. |
Pan |
EGFR, IC50: 1.48 nM |
| S1019 |
Canertinib (CI-1033) |
Canertinib (CI-1033, PD183805) is a pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, no activity to PDGFR, FGFR, InsR, PKC, or CDK1/2/4. Phase 3. |
Pan |
EGFR, IC50: 1.5 nM |
| S1486 |
AEE788 (NVP-AEE788) |
AEE788 (NVP-AEE788) is a potent inhibitor of EGFR and HER2/ErbB2 with IC50 of 2 nM and 6 nM, less potent to VEGFR2/KDR, c-Abl, c-Src, and Flt-1, does not inhibit Ins-R, IGF-1R, PKCα and CDK1. Phase 1/2. |
Pan |
EGFR, IC50: 2 nM |
| S8724 |
Lazertinib |
Lazertinib (YH25448,GNS-1480) is a potent, highly mutant-selective and irreversible EGFR-TKI with IC50 values of 1.7 nM, 2 nM, 5 nM, 20.6 nM and 76 nM for Del19/T790M, L858R/T790M, Del19, L85R and Wild type EGFR respectively, showing much higher IC50 values aganist ErbB2 and ErbB4. |
Pan |
L858R/T790M EGFR, IC50: 2 nM; WT EGFR, IC50: 76 nM |
| S1194 |
CUDC-101 |
CUDC-101 is a potent multi-targeted inhibitor against HDAC, EGFR and HER2 with IC50 of 4.4 nM, 2.4 nM, and 15.7 nM, and inhibits class I/II HDACs, but not class III, Sir-type HDACs. Phase 1. |
Pan |
EGFR, IC50: 2.4 nM |
| S8584 |
Theliatinib (HMPL-309) |
Theliatinib (HMPL-309) is a highly potent EGFR inhibitor with Ki value of 0.05 nM against the wild type EGFR and IC50 values of 3 nM and 22 nM against EGFR and EGFR T790M/L858R mutant. It demonstrats 50 fold greater selectivity for EGFR compared to 72 other kinases. |
Pan |
WT EGFR, IC50: 3 nM |
| S7358 |
Poziotinib |
Poziotinib is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2. |
Pan |
HER1, IC50: 3.2 nM |
| S2192 |
Sapitinib (AZD8931) |
Sapitinib (AZD8931) is a reversible, ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4 nM, 3 nM and 4 nM in cell-free assays, more potent than Gefitinib or Lapatinib against NSCLC cell, 100-fold more selective for the ErbB family than MNK1 and Flt. Phase 2. |
Pan |
EGFR, IC50: 4 nM |
| S8814 |
zipalertinib |
TAS6417 (CLN-081, TPC-064) is a novel EGFR inhibitor that targets EGFR exon 20 insertion mutations while sparing wild-type (WT) EGFR. IC50 values ranges from 1.1 ± 0.1 to 8.0 ± 1.1 nmol/L. |
Pan |
EGFR (T790M), IC50: 4.1 nM; EGFR (L861Q), IC50: 5.5 nM; EGFR WT, IC50: 8 nM |
| S2727 |
Dacomitinib |
Dacomitinib is a potent, irreversible pan-ErbB inhibitor, mostly to EGFR with IC50 of 6 nM in a cell-free assay. Dacomitinib inhibits ERBB2 and ERBB4 with IC50 of 45.7 nM and 73.7 nM, respectively. Dacomitinib is effective against NSCLCs with EGFR or ERBB2 mutations (resistant to gefitinib) as well as those harboring the EGFR T790M mutation. Dacomitinib inhibits cell growth and induces apoptosis. Phase 2. |
Pan |
EGFR, IC50: 6.0 nM |
| S6881 |
JND3229 |
JND3229 is a potent reversible inhibitor of EGFRC797S with an IC50 value of 5.8 nM. JND3229 also potently suppresses EGFRL858R/T790M and EGFRWT with IC50 values of 30.5 nM and 6.8 nM, respectively. |
Pan |
EGFR WT, IC50: 6.8 nM |
| S2755 |
Varlitinib |
Varlitinib (ARRY334543) is a selective and potent ErbB1(EGFR) and ErbB2(HER2) inhibitor with IC50 of 7 nM and 2 nM, respectively. Phase 2. |
Pan |
ErbB1, IC50: 7 nM |
| S0711 |
Canertinib dihydrochloride |
Canertinib (CI-1033, PD-183805, compound 18) dihydrochloride is a potent and irreversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. Canertinib dihydrochloride inhibits cellular EGFR and ErbB2 autophosphorylation with IC50 of 7.4 nM and 9 nM, respectively. |
Pan |
EGFR, IC50: 7.4 nM |
| S2111 |
Lapatinib |
Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death. |
Pan |
EGFR, IC50: 10.8 nM |
| S1028 |
Lapatinib Ditosylate |
Lapatinib Ditosylate is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. |
Pan |
EGFR, IC50: 10.8 nM |
| S8852 |
Pyrotinib dimaleate |
Pyrotinib dimaleate is a potent and selective irreversible dual tyrosine kinase inhibitor of EGFR and HER2 with IC50 of 0.013 μM and 0.038 μM, respectively. |
Pan |
EGFR, IC50: 0.013 μM |
| S1056 |
AC480 (BMS-599626) |
AC480 (BMS-599626) is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM, ~8-fold less potent to HER4, >100-fold to VEGFR2, c-Kit, Lck, MET etc. Phase 1. |
Pan |
HER1, IC50: 20 nM |
| S7206 |
CNX-2006 |
CNX-2006 is a novel irreversible mutant-selective EGFR inhibitor with IC50 of < 20 nM, with very weak inhibition at wild-type EGFR. |
Pan |
mutant EGFR, IC50: <20 nM |
| S2784 |
TAK-285 |
TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. Phase 1. |
Pan |
EGFR/HER1, IC50: 23 nM |
| S7824 |
Nazartinib (EGF816) |
Nazartinib (EGF816, NVS-816) is a covalent, irreversible, mutant-selective EGFR inhibitor that has nanomolar inhibitory potency against activating mt (L858R, ex19del) and T790M mt, with up to 60-fold selectivity over wild type (wt) EGFR in vitro. |
Pan |
mutant EGFR, Ki: 0.031 μM |
| S2150 |
Neratinib |
Neratinib is a highly selective HER2 and EGFR inhibitor with IC50 of 59 nM and 92 nM in cell-free assays; weakly inhibits KDR and Src, no significant inhibition to Akt, CDK1/2/4, IKK-2, MK-2, PDK1, c-Raf and c-Met. Phase 3. |
Pan |
EGFR, IC50: 92 nM |
| S6805 |
Tyrphostin AG-528 |
Tyrphostin AG-528 (Tyrphostin B66) is a potent inhibitor of epidermal growth factor receptors (EGFR) and ErbB2/HER2 with IC50 of 4.9 μM and 2.1 μM, respectively. Tyrphostin AG-528 exhibits anticancer activity. |
Pan |
EGFR, IC50: 4.9 μM |
| S6813 |
Mobocertinib (TAK788) |
Mobocertinib (TAK788, AP32788), an investigational TKI, is a potent, selective preclinical inhibitor of epidermal growth factor receptor (EGFR) and HER2 mutations. Mobocertinib (TAK788) is an antineoplastic agent. |
Pan |
|
| S8294 |
Olmutinib (BI 1482694) |
Olmutinib (BI 1482694) is a novel third-generation epidermal growth factor receptor (EGFR) mutation-specific tyrosine kinase inhibitor (TKI). Also a potent inhibitor of Bruton's tyrosine kinase. |
Pan |
|
| S2250 |
EGCG ((-)-Epigallocatechin Gallate) |
EGCG ((-)-Epigallocatechin Gallate) is the main catechin extraction of green tea that inhibits telomerase and DNA methyltransferase. EGCG blocks the activation of EGF receptors and HER-2 receptors. ECGG inhibits fatty acid synthase and glutamate dehydrogenase activity. |
Pan |
|
